These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38313767)

  • 1. Association of Bowel Urgency With Quality-of-Life Measures in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From Phase 3 LUCENT-1 (Induction) and LUCENT-2 (Maintenance) Studies.
    Long MD; Schreiber S; Hibi T; Gibble TH; Fisher DA; Park G; Moses RE; Higgins PDR; Lindsay JO; Lee SD; Escobar R; Jairath V
    Crohns Colitis 360; 2024 Jan; 6(1):otae001. PubMed ID: 38313767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mirikizumab Improves Quality of Life in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies.
    Sands BE; Feagan BG; Hunter Gibble T; Traxler KA; Morris N; Eastman WJ; Schreiber S; Jairath V; Long MD; Armuzzi A
    Crohns Colitis 360; 2023 Oct; 5(4):otad070. PubMed ID: 38034882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early and Sustained Symptom Control with Mirikizumab in Patients with Ulcerative Colitis in the Phase 3 LUCENT Program.
    Danese S; Dignass A; Matsuoka K; Ferrante M; Long M; Redondo I; Moses R; Maier S; Hunter Gibble T; Morris N; Milch C; Abreu MT
    J Crohns Colitis; 2024 Jun; ():. PubMed ID: 38869019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resolving Histological Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes.
    Magro F; Pai RK; Kobayashi T; Jairath V; Rieder F; Redondo I; Lissoos T; Morris N; Shan M; Park M; Peyrin-Biroulet L
    J Crohns Colitis; 2023 Oct; 17(9):1457-1470. PubMed ID: 37057827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Effect of Mirikizumab Treatment on Bowel Urgency in Patients with Moderately to Severely Active Ulcerative Colitis and the Clinical Relevance of Bowel Urgency Improvement for Disease Remission.
    Dubinsky MC; Clemow DB; Hunter Gibble T; Li X; Vermeire S; Hisamatsu T; Travis SPL
    Crohns Colitis 360; 2023 Jan; 5(1):otac044. PubMed ID: 36777368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.
    Sands BE; D'Haens G; Clemow DB; Irving PM; Johns JT; Hunter Gibble T; Abreu MT; Lee S; Hisamatsu T; Kobayashi T; Dubinsky MC; Vermeire S; Siegel CA; Peyrin-Biroulet L; Moses RE; Milata J; Arora V; Panaccione R; Dignass A
    Inflamm Bowel Dis; 2024 Mar; ():. PubMed ID: 38459910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of mirikizumab as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the global phase 3 LUCENT-1 and LUCENT-2 studies.
    Kobayashi T; Matsuoka K; Watanabe M; Hisamatsu T; Hirai F; Milata J; Li X; Morris N; Arora V; Ishizuka T; Matsuo K; Satoi Y; Milch C; Hibi T
    Intest Res; 2024 Apr; 22(2):172-185. PubMed ID: 38720466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.
    D'Haens G; Dubinsky M; Kobayashi T; Irving PM; Howaldt S; Pokrotnieks J; Krueger K; Laskowski J; Li X; Lissoos T; Milata J; Morris N; Arora V; Milch C; Sandborn W; Sands BE;
    N Engl J Med; 2023 Jun; 388(26):2444-2455. PubMed ID: 37379135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials.
    D'Haens G; Higgins PDR; Peyrin-Biroulet L; Sands BE; Lee S; Moses RE; Redondo I; Escobar R; Gibble TH; Keohane A; Morris N; Zhang X; Arora V; Kobayashi T
    Inflamm Bowel Dis; 2024 Jan; ():. PubMed ID: 38271613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychometric evaluation of the Urgency NRS as a new patient-reported outcome measure for patients with ulcerative colitis.
    Dubinsky MC; Shan M; Delbecque L; Lissoos T; Hunter T; Harding G; Stassek L; Andrae D; Lewis JD
    J Patient Rep Outcomes; 2022 Nov; 6(1):114. PubMed ID: 36334163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upadacitinib Induction and Maintenance Therapy Improves Abdominal Pain, Bowel Urgency, and Fatigue in Patients With Ulcerative Colitis: A Post Hoc Analysis of Phase 3 Data.
    Danese S; Tran J; D'Haens G; Rubin DT; Aoyama N; Zhou W; Ilo D; Yao X; Sanchez Gonzalez Y; Panaccione R
    Inflamm Bowel Dis; 2023 Nov; 29(11):1723-1729. PubMed ID: 36790041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of biological interventions for ulcerative colitis on health-related quality of life.
    LeBlanc K; Mosli MH; Parker CE; MacDonald JK
    Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD008655. PubMed ID: 26393522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Bowel Urgency on Quality of Life and Clinical Outcomes in Patients With Ulcerative Colitis.
    Dubinsky MC; Panaccione R; Lewis JD; Sands BE; Hibi T; Lee SD; Naegeli AN; Shan M; Green LA; Morris N; Arora V; Bleakman AP; Belin R; Travis S
    Crohns Colitis 360; 2022 Jul; 4(3):otac016. PubMed ID: 36777426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in health-related quality of life and associations with improvements in clinical efficacy: a Phase 2 study of mirikizumab in patients with ulcerative colitis.
    Dubinsky MC; Jairath V; Feagan BG; Naegeli AN; Tuttle J; Morris N; Shan M; Arora V; Lissoos T; Agada N; Hibi T; Sands BE
    BMJ Open Gastroenterol; 2023 Mar; 10(1):. PubMed ID: 37001911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
    Peyrin-Biroulet L; Hart A; Bossuyt P; Long M; Allez M; Juillerat P; Armuzzi A; Loftus EV; Ostad-Saffari E; Scalori A; Oh YS; Tole S; Chai A; Pulley J; Lacey S; Sandborn WJ;
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):128-140. PubMed ID: 34798039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mirikizumab: A New Therapeutic Option for the Treatment of Ulcerative Colitis.
    Choi D; Sheridan H; Bhat S
    Ann Pharmacother; 2024 Feb; ():10600280241229742. PubMed ID: 38344998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction and Maintenance Treatment With Upadacitinib Improves Health-Related Quality of Life in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 Study Results.
    Panés J; Loftus EV; Higgins PDR; Lindsay JO; Zhou W; Yao X; Ilo D; Phillips C; Tran J; Sanchez Gonzalez Y; Vermeire S
    Inflamm Bowel Dis; 2023 Sep; 29(9):1421-1430. PubMed ID: 36645051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis.
    Sandborn WJ; Ferrante M; Bhandari BR; Berliba E; Feagan BG; Hibi T; Tuttle JL; Klekotka P; Friedrich S; Durante M; Morgan-Cox M; Laskowski J; Schmitz J; D'Haens GR
    Gastroenterology; 2020 Feb; 158(3):537-549.e10. PubMed ID: 31493397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies.
    Chua L; Friedrich S; Zhang XC
    Clin Pharmacokinet; 2023 Oct; 62(10):1479-1491. PubMed ID: 37610533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring Disease Remission and Bowel Urgency Severity Among Adults with Moderate to Severe Ulcerative Colitis: A Qualitative Study.
    Dubinsky MC; Newton L; Delbecque L; Hunter T; Guobyte A; Naegeli AN; McFadden S; Donaldson J; Symonds T; Lewis JD
    Patient Relat Outcome Meas; 2022; 13():287-300. PubMed ID: 36582542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.